Work

O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.05.018

Authors: Hiroki Hara, Taroh Satoh, Takashi Kojima, Satoru Motoyama, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Aiyang Tao, Ningning Ding, Ken Kato

Institutions: Saitama Cancer Center, The University of Osaka, National Cancer Center Hospital East, Akita University Hospital, Shizuoka Cancer Center, St. Marianna University School of Medicine, Hiroshima University, BeiGene (China), National Cancer Center Hospital

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4286510199

FWCI: 0.211

Cites:

Cited by: 1

Related to: 10